Free Trial
NASDAQ:ADIL

Adial Pharmaceuticals 11/14/2023 Earnings Report

Adial Pharmaceuticals logo
$0.45 +0.00 (+0.27%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.27%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adial Pharmaceuticals EPS Results

Actual EPS
-$1.14
Consensus EPS
-$1.14
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Adial Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adial Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Adial Pharmaceuticals' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Adial Pharmaceuticals Earnings Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company focused on developing treatments for alcohol-related disorders. The company’s lead product candidate, AD04, is an investigational intravenous therapy designed to accelerate the metabolism of ethanol in the blood, potentially reducing the severity and duration of acute alcohol intoxication. Adial applies a bio-mimetic enzymatic approach to address a significant unmet medical need in emergency and clinical settings.

Adial’s research and development efforts center on advancing AD04 through preclinical and clinical studies, with the goal of establishing safety and efficacy profiles that support regulatory approval. The company’s proprietary technology platform leverages engineered enzymes to break down ethanol, differentiating its approach from traditional supportive care measures. By targeting the root cause of intoxication rather than merely managing symptoms, Adial aims to deliver a therapeutic option for patients, clinicians and first responders.

Headquartered in the United States, Adial Pharmaceuticals maintains its operations in Florida, where it oversees product manufacturing partnerships, clinical trial coordination and regulatory interactions. The company has built a network of collaborators and contract research organizations to facilitate its clinical programs and to position AD04 for potential global development following initial regulatory review.

Adial’s leadership team is led by Michael Sindoni, who serves as President and Chief Executive Officer. Under his guidance, the company has prioritized strategic research alliances, intellectual property protection and the pursuit of key regulatory milestones. Moving forward, Adial plans to advance its clinical pipeline while exploring additional therapeutic applications of its enzymatic technology platform.

View Adial Pharmaceuticals Profile

More Earnings Resources from MarketBeat